ClinicalTrials.gg
Status unknownNCT01770964Updated Jan 18, 2013

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

A Phase 4 interventional study of Pregabalin and placebo in Diabetes Mellitus and Painful Distal Symmetric Sensorimotor Polyneuropathy, sponsored by Analgesic Solutions. Status unknown at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-18.

Sponsored by Analgesic Solutions · Phase 4, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jan 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
1,190th of 2,501
90 · median 82
Started
2012
with 140 others
Phase 4
215 of 3,022
15 open now
Registered
1,399th of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,190th largest by planned enrollment of the 2,501 interventional ones that give a count, is one of 141 that started in 2012, is one of 215 in phase 4, and was the 1,399th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

The difference between active treatment and placebo in a clinical trial of an analgesic appears to depend on a variety of factors other than the actual efficacy of the drug itself, including various aspects of study design and conduct. One potential such factor is how information about the study is presented to research staff and patients. The purpose of this study is to examine the impact of different presentations of information on the difference between pregabalin and placebo observed in a clinical trial in patients with painful diabetic neuropathy.

03

Conditions studied

  • Diabetes Mellitus
  • Painful Distal Symmetric Sensorimotor Polyneuropathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingly signs and dates an Form (ICF) that is approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), prior to the conduct of any study-specific procedures;
  • Is at least 18 years old;
  • Has a diagnosis of type 1 or type 2 diabetes and painful distal symmetric sensorimotor polyneuropathy;
  • Has experienced a minimum duration of PDN of at least 6 months;
  • Is on stable diabetic medication that is not expected to change during the study;
  • Has a worst pain intensity over the past 24 hours as a 4 or higher on a 0-10 numerical rating scale at Screening;
  • And is able to read and communicate meaningfully in English and comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • Has a psychiatric or psychological disorder that in the judgment of the Investigator would interfere with the completion of the study, confound the study results, or pose subject risk;
  • Has an uncontrolled, medical condition that in the judgment of the Investigator may contraindicate use of pregabalin or participation in the study (e.g., hepatic, respiratory, or hematologic illness; cardiovascular disease; or symptomatic peripheral vascular disease);
  • Has experience as an investigator or a study staff member in clinical trials research in a role that involved direct patient contact;
  • Participated in any of the following studies: Analgesic Solutions Protocol # ALPMF.SOW.0007, Analgesic Solutions Protocol # ALPMF.SOW.0007.02, or Astellas Protocol # E05-CL-3004;
  • Has pain of other origin that might confound assessment of PDN;
  • Has major skin ulceration;
  • Has had an amputation other than toes;
  • Has a history of suicide attempt within the past 1 year;
  • Reports current suicidal ideation within the past 1month;
  • Has history of kidney disease that is likely to decrease ;
  • Has creatinine clearance below 60 as calculated by Cockroft-Gault equation for serum creatinine;
  • Has a history of drug or alcohol abuse within the past 1 year;
  • Has , intolerance, or allergy to pregabalin or gabapentin;
  • Subject is pregnant, is considering becoming pregnant during the study, is breastfeeding or unwilling to use adequate during the study;
  • Participated in another clinical trial within the past month;
  • Is involved in an ongoing or settled worker's compensation claim, disability, or litigation;
  • Has a known failure to respond to pregabalin or gabapentin at a clinically relevant dose due to either efficacy or tolerability;
  • Or has taken opioids on an as-needed basis within 1week of Screening, or has taken pregabalin or gabapentin within 30 days of screening. Subjects on stable doses opioids, antidepressants, non-steroidal anti-inflammatory drugs, or low-dose aspirin will be allowed to participate in the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Other
    Training Type A, pregabalin

    Subjects randomized to receive pregabalin at a site that received training Type A

    Drug: Pregabalin · Behavioral: Training Type A

  • Other
    Training Type B, pregabalin

    Subjects randomized to receive pregabalin at a site that received training Type B

    Drug: Pregabalin · Behavioral: Training Type B

  • Other
    Training Type A, placebo

    Subjects randomized to receive placebo at a site that received training Type A

    Drug: placebo · Behavioral: Training Type A

  • Other
    Training Type B, placebo

    Subjects randomized to receive placebo at a site that received training Type B

    Drug: placebo · Behavioral: Training Type B

Interventions

  • Drugplacebo
  • BehavioralTraining Type A
  • BehavioralTraining Type B
06

What researchers measure

Primary outcomes

  1. change in pain severity rating

    Time frame: Screening/Visit 1 (Day 1) and Visit 4 (Day 15-18)

07

Study locations

6 of 6 sites recruiting
  • St. Elizabeth's Medica Center
    Brighton, Massachusetts 02135, United States
    Recruiting
    • Cameron Keith, BSN, RN · Contact617-789-2763
    • Frederic J Gerges, MD · Principal investigator
    • Andrew L Sternlicht, MD · Sub investigator
    • Magid A Al-Kimawi, MD · Sub investigator
  • MedVadis Research Corporation
    Watertown, Massachusetts 02472, United States
    Recruiting
    • Alice Brown, MD · Contact617-744-1310
    • Alice Brown, MD · Sub investigator
    • Egilius Spierings, MD Phd · Principal investigator
  • Neuro Care Medical Associates
    Johnson City, New York 13790, United States
    Recruiting
    • Kathe Rooney · Contact607-729-1521
    • Aamir Rasheed, MD · Principal investigator
    • Taseer Ahmed Minhas, MD · Sub investigator
    • Sherrie A Adler, FNP · Sub investigator
  • University of Rochester
    Rochester, New York 14618, United States
    Recruiting
    • Maria Frazer · Contact585-340-8926
    • Armando A Villarreal, MD · Principal investigator
    • John D Markman, MD · Sub investigator
  • Blair Medical Associates, Inc.
    Altoona, Pennsylvania 16602, United States
    Recruiting
    • Julia E Benton, RN, CCRC · Contact814-946-7569
    • Anthony J Bartkowiak, Jr., MD, FACP, CPI · Principal investigator
    • Jessica L Dilling, CRNP · Sub investigator
    • Andrea Jill Runk, CRNP · Sub investigator
    • Harry L Penny, DPM · Sub investigator
  • Clinical Partners
    Johnston, Rhode Island 02919, United States
    Recruiting
    • Caroline DiGiulio, RN · Contact401-454-3800
    • Albert J Marano, MD · Principal investigator
    • William J Beliveau, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2012
First posted
Jan 18, 2013
Start
Dec 2012
Primary completionEst.
Jul 2013
CompletionEst.
Jul 2013
Last update
Jan 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01770964
Lead sponsor
Analgesic Solutions
Responsible party
Sponsor
First posted
Jan 18, 2013
Start date
Dec 2012
Primary completion
Jul 2013 (estimated)
Completion
Jul 2013 (estimated)
Last update
Jan 18, 2013

Study contacts

Jeremiah J Trudeau, PhD
principal investigator · Analgesic Solutions

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion